Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.72 |
| ▸ | ZAP70 | P43403 | 15/20 | 0.72 |
| ▸ | SRC | P12931 | 14/20 | 0.72 |
| ▸ | CDK2 | P24941 | 8/20 | 0.72 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038582 | 0.83 | SYK (0.74) | SYKZAP70SRCCDK2KDR | |
| SCHEMBL14216294 | 0.81 | SYK (0.77) | SYKZAP70SRCCDK2KDR | |
| SCHEMBL14216119 | 0.81 | SYK (0.77) | SYKZAP70SRCCDK2KDR | |
| SCHEMBL14216287 | 0.79 | SYK (0.72) | SYKZAP70SRCCDK2KDR | |
| SCHEMBL14216022 | 0.79 | SYK (0.79) | SYKZAP70SRCCDK2KDR | |
| SCHEMBL5034160 | 0.79 | SYK (0.72) | SYKZAP70SRCCDK2KDR | |
| SCHEMBL5038586 | 0.79 | SYK (1.00) | SYKZAP70SRCCDK2CDK4 | |
| SCHEMBL5037349 | 0.79 | SYK (0.79) | SYKZAP70SRCCDK2CDK4 | |
| SCHEMBL13924509 | 0.77 | SYK (1.00) | SYKZAP70SRCCDK2 | |
| SCHEMBL5036868 | 0.77 | SYK (0.76) | SYKZAP70SRCCDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605946-B1 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1605946-B1 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1605946-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004087699-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | TSLP, JAK1, SERPINB1 | SYK 463/4885ZAP70 82/4885SRC 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.